Skip to main content
PMC home page
BMC Hematology logoLink to BMC Hematology
. 2018 Nov 6;18:30. doi: 10.1186/s12878-018-0128-x

Storage related haematological and biochemical changes in Plasmodium falciparum infected and sickle cell trait donor blood

Enoch Aninagyei 1,✉, Emmanuel Tetteh Doku 2, Patrick Adu 3, Alexander Egyir-Yawson 1, Desmond Omane Acheampong 1,✉
PMCID: PMC6220467  PMID: 30450212

Abstract

Background

In sub-Saharan Africa where sickle cell trait (SCT) and malaria is prevalent, significant proportions of blood donors may be affected by one or more of these abnormalities. The haemato-biochemical properties of SCT and asymptomatic malaria in donor blood have not been evaluated. This study evaluated the haemato-biochemical impact of SCT and asymptomatic malaria infections in citrate-phosphate-dextrose-adenine (CPDA-1) stored donor blood units.

Methods

Fifty-milliliters of sterile CPDA-1 anti-coagulated blood were drained into the sample pouch attached to the main blood bag. Ten units each of sickle cell/malaria negative, sickle cell and malaria positive blood were analyzed. Baseline and weekly haematological profiling and week 1, 3 and 5 concentrations of plasma haemoglobin, % haemolysis, sodium, potassium and chloride and lactate dehydrogenase (LDH) were assayed. Differences between baseline and weekly data were determined using one-way analysis of variance (ANOVA) and Kruskal-Wallis test, whereas differences between baseline parameters and week 1–3 data pairs were determined using paired t-test. P-value < 0.05 was considered statistically significant.

Results

Storage of SCT and malaria infected blood affected all haematological cell lines. In the SCT donors, red blood cells (RBC) (4.75 × 1012/L ± 1.43baseline to 3.49 × 1012/L ± 1.09week-5), haemoglobin (14.45 g/dl ± 1.63baseline to 11.43 g/dl ± 1.69week-5) and haematocrit (39.96% ± 3.18baseline to 33.22% ± 4.12week-5) were reduced. In the asymptomatic malaria group, reductions were observed in RBC (5.00 × 1012/L ± 0.75baseline to 3.72 × 1012/L ± 0.71week-5), haemoglobin (14.73 g/dl ± 1.67baseline to 11.53 g/dl ± 1.62week-5), haematocrit (42.72% ± 5.16baseline to 33.38% ± 5.80week-5), mean cell haemoglobin concentration (35.48 g/dl ± 1.84baseline to 35.01 g/dl ± 0.64week-5) and red cell distribution width coefficient of variation (14.81% ± 1.54baseline to 16.26% ± 1.37week-5). Biochemically, whereas plasma LDH levels significantly increased in asymptomatic malaria blood donors (319% increase at week 5 compared to baseline), SCT blood donors had the most significant increase in plasma potassium levels at week 5 (382% increase). Sodium ions significantly reduced in SCT/malaria negative and sickle cell trait blood at an average rate of 0.21 mmol/L per day. Moreover, elevations in lymphocytes-to-eosinophils and lymphocytes-to-neutrophils ratios were associated with SCT and malaria positive blood whilst elevation lymphocytes-to-basophils ratio was exclusive to malaria positive blood.

Conclusion

Severe storage lesions were significant in SCT or malaria positive donor blood units. Proper clinical evaluation must be done in prospective blood donors to ensure deferral of such donors.

Electronic supplementary material

The online version of this article (10.1186/s12878-018-0128-x) contains supplementary material, which is available to authorized users.

Keywords: Sickle cell trait donor, Asymptomatic malaria donor, % haemolysis, Storage lesions, Plasma haemoglobin, Biochemical changes, Blood transfusion

Background

There are two major outcomes of Plasmodium infections, thus symptomatic and asymptomatic infections. Symptomatic infections occur in patients with compromised anti-disease immunity [1] and asymptomatic infections occur in individuals with competent malaria immunity [2]. Despite being asymptomatic, parasites may be present in red blood cells, but at low density and can persist for many months [3]. Prevalence of asymptomatic Plasmodium infections differs from one geographical region to another. In Brazil, Solomon Islands and Cambodia, asymptomatic malaria has been found to be 37.5, 82.2 and 92% respectively [4–6]. In Africa, the prevalence of asymptomatic malaria in blood donors in Ghana has been found to be 10.0% [7]. In Cameroon, Senegal, Benin and Nigeria, asymptomatic malaria parasitaemia in blood donors have been found to be 27.54% [8], 65.3% [9], > 30% [10] and 40% [11] respectively.

Sickle cell haemoglobin result when valine substitutes for glutamic acid at position 6 of the β-globin chain. This mutation consequently changes the physico-chemical properties of the haemoglobin molecule [12]. A person who inherits haemoglobin S from one parent and haemoglobin A (normal gene) from the other has a sickle cell trait (SCT) or is said to be a carrier of sickle cell disease [13]. The prevalence of sickle cell trait (SCT) is highest in Africans and people of African descent. In Africa, Nigeria probably has the highest number of people with SCT as close to 30% of the population carry haemoglobin S gene [14]. Liberia, Ghana and Uganda have 10–15% of their population being carriers of haemoglobin S gene [13, 15, 16]. Cameroon and Gabon have haemoglobin S gene prevalence of 19 and 22%, respectively [17, 18]. SCT individuals are clinically healthy to donate blood [19]. Populations with high prevalence of sickle cell trait and asymptomatic Plasmodium falciparum infections can result in high number of healthy blood donors with sickle cell trait and/or asymptomatic Plasmodium infections. In Kenya and Nigeria, proportion of their blood donor population who were sickle cell carriers were 3.9 and 27.1% respectively [20, 21]. In Ghana, studies done in Brong Ahafo and Greater Accra regions reported prevalence of SCT in blood donors to be 12.5 and 11.3% respectively [12, 22].

Majority of the blood banks in SSA still practice whole blood banking [23, 24]. Although donated blood units are stored in anticoagulants supplemented with phosphate, dextrose, and/or adenine to assure long-term viability, storage lesions are inevitable when blood is stored for long periods [25]. RBC storage lesions include decreased RBC stability, alterations in various metabolites and the metabolic status of the cell, including decrease of intracellular adenosine triphosphate (ATP) and 2,3-biphosphoglycerate (2,3 BPG) [26–28]. These changes in RBC during storage have been known for years but the exact changes conferred on blood collected from SCT donors and those infected with Plasmodium parasites are unknown. The aim of this study therefore was to evaluate, for the first time, the haematological and biochemical variations in sickle cell trait blood and blood infected with Plasmodium falciparum stored in CPDA-1 anticoagulant up to 35 days.

Methods

Study design

This cross-sectional laboratory based experimental study was done in sterile blood units. Donors were selected according to Medical History Guide for Donor Selection [29].

Donor selection, phlebotomy and specimen collection

The selections of the healthy blood donors were double-blinded as researchers and National Blood Service Ghana staff could not link the study specimens to any donor. Participant consent form was signed by all participated donors. Blood was collected from each of the donors following a modification of the technique described by Cheesbrough [25]. For the purpose of the study, 7 ml of the CDPA-1 anticoagulant was allowed into the sample pouch attached to the main blood bag, which was filled with the initial 50 ml of whole blood. The rest of the whole blood was directed into the main blood bag.

Inclusion criteria

Donor blood included in the study were TTIs-negative blood with baseline biochemical parameters that fell within these ranges; haemoglobin 12.5–18.00 g/dl, plasma haemoglobin-0 g/dl, percentage haemolysis-0.0%, plasma sodium, potassium, chloride and LDH that fell within these respective ranges 135-145mmo/l, 3.0–5.2 mmol/l, 95-108 mmol/l and 100-250 U/L.

Laboratory procedures

Post-phlebotomy laboratory procedures were done as follows: 5 ml of well mixed whole blood was aspirated into plain glass vacutainer tubes (All-Pro, Dusseldorf, Germany). Portion of the blood was used to screen for transfusion-transmitted infections (TTIs) using fourth generation enzyme immuno-assay (Abnova, Taiwan). The ELISA microtitre plate wells were pre-coated with hepatitis B surface monoclonal antibodies, gp36/gp41, hepatitis C antigens (core, NS3 and NS5) and Treponema pallidum antigens for qualitative detection of hepatitis B virus, HIV I&II, hepatitis C virus and Treponema pallidum respectively. Donor screening of sickle cells was done as described by Antwi-Baffour [13] whilst phenotyping was done in alkaline medium (pH = 8.6). Separation of haemolysate was done on cellulose acetate paper using 250 V voltage and 50 mA current for 30 min. The separated haemoglobin molecules were interpreted against pooled haemoglobin AFSC controls. Screening of malaria was done with PfHRP-2/Pf-LDH SD Bioline rapid diagnostic test kit (Gyeonggi-do, Republic of Korea). The kit detected Plasmodium falciparum specific HRP-2 proteins and lactate dehydrogenase enzymes. Five microliters of whole blood were dropped on the sample column of the rapid test kit. Four drops of assay diluent (PfHRP-2/Pf-LDH SD Bioline, Korea) were added to the buffer window of the kit. Results were read after 15 min. Baseline haematological parameters using 5-part differential Urit-5160 (Guangxi, China), plasma electrolytes (sodium, potassium and chloride) measured by FT-320 electrolyte analyzer (China), lactate dehydrogenase (measured by PKL-125 Italia fully automated chemistry analyzer using ELItech LDH kinetic reagent, France), plasma haemoglobin (Urit-5160, China) and percentage haemolysis calculated by using formulae used by Sawant et al. [30] was done on same day of blood collection (baseline). The donor whole blood study samples were stored in the blood bank refrigerator (Fiocchetti Scientific Refrigerator, Italy) for 5 weeks. Internal storage temperature was taken twice daily. Haematological parameters were determined weekly for 5 weeks whilst plasma haemoglobin, % haemolysis, plasma electrolytes and LDH were measured at the end of week 1, week 3 and week 5.

Data processing and statistical analysis

Baseline and weekly data was entered into Microsoft Excel 2010. Statistical analysis was done by SPSS Version 24 (Chicago, IL, USA). Based on SCT status and/or asymptomatic malaria infection status, participants were grouped into three: SCT blood donors, asymptomatic malaria blood donors and no SCT/asymptomatic malaria blood donors for subsequent analysis. Differences between baseline and the 5 weeks haematological profile and biochemical data set were determined by one-way analysis of variance (ANOVA) and Kruskal-Wallis test statistical models. Differences between baseline haematological parameters and week 1 to 3 data pair were determined by paired student T-test. P-value of < 0.05 was considered statistically significant.

Results

Storage related changes in TWBC and WBC differential counts

The study recorded significant changes in total white blood cells (TWBC) and WBC differential in all the three donor groups (Table 1). There were consecutive reductions in TWBC and neutrophil proportion in all donor groups. Whereas the largest significant TWBC reduction occurred in the sickle cell/malaria negative group (62.3% reduction in week 5), the largest significant reduction in neutrophil% occurred in the SCT donors (53.9% reduction in week 5). However, there were successive increases in %lymphocytes, basophils and monocytes in all donor groups when weekly estimates were compared to baseline values. Whereas the highest increase in %lymphocytes occurred in the sickle cell/malaria negative donors (84.3% increase compared to baseline), the highest %monocyte increase occurred in the SCT donor group (75.6% increase compared to baseline). Additionally, although there was a consecutive reduction in %eosinophil count in the SCT group, the changes in %eosinophil count fluctuated in the sickle cell/malaria negative, and the asymptomatic malaria donor groups.

Table 1.

Leukocytes and percentage differential storage changes in donor blood

TWBC and differentials Baseline Mean Week 1 Mean (%∆) Week 2 Mean (%∆) Week 3 Mean (%∆) Week 4 Mean (%∆) Week 5 Mean (%∆) P-value
Sickle cell/malaria negative donor blood
 TWBCx109/L 5.63 3.89(−30.9) 2.90(−48.4) 2.49(−55.7) 2.27(− 59.6) 2.09(−62.3) 0.001*,a
 Neut % 66.18 60.09(− 9.2) 52.77(−20.2) 49.49(− 25.2) 44.21(− 33.2) 40.88(− 38.2) 0.054b
 Lymp % 27.28 33.42(22.5) 39.83(46.0) 41.92(53.6) 46.94(72.0) 50.28(84.3) 0.092b
 Eos % 3.03 2.73(−9.9) 2.42(−20.1) 3.32(9.5) 3.00(−0.9) 3.49(15.2) 0.845a
 Mon % 3.27 3.52(7.6) 4.64(41.9) 4.94(51.1) 5.50(68.2) 4.96(51.6) 0.009b
 Bas % 0.24 0.25(4.1) 0.35(45.8) 0.33(37.5) 0.35(45.8) 0.39(62.5) 0.033b
Sickle cell trait donor blood
 TWBCx109/L 6.36 5.08 (−20.1) 4.42 (−30.5) 4.24 (−33.3) 3.74 (−41.2) 3.57 (−43.8) 0.001*,b
 Neut % 56.26 50.91 (−9.5) 39.58(−29.6) 32.64 (−41.9) 31.99 (− 43.1) 25.90 (− 53.9) 0.001*,b
 Lymp % 37.50 43.06 (14.8) 51.48 (37.3) 61.46 (63.9) 62.79 (67.4) 66.28 (76.7) 0.001*,1
 Eos % 3.34 2.45 (−26.6) 2.50 (− 25.1) 1.56 (−53.3) 1.69 (−49.4) 2.77 (−17.0) 0.020a
 Mon % 2.71 3.59 (32.4) 3.94 (45.4) 4.02 (48.3) 3.24 (19.5) 4.76 (75.6) 0.179b
 Bas % 0.20 0.20 (0.0) 0.38 (90.0) 0.32 (60.0) 0.30 (50.0) 0.29 (45.0) 0.069b
Asymptomatic malaria donor blood
 TWBCx109/L 6.08 4.49 (−26.1) 4.13 (−32.1) 3.77 (−37.9) 3.54 (−41.7) 3.21 (−47.2) 0.001a
 Neut % 72.09 60.89 (−15.5) 47.78 (−33.7) 39.79 (−44.8) 42.91 (−40.4) 36.07 (− 49.9) 0.001*,b
 Lymp % 31.67 32.53 (2.7) 45.65 (44.1) 52.53 (65.8) 49.52 (56.3) 55.63 (75.6) 0.001*,b
 Eos % 2.38 2.50 (5.0) 2.01 (−15.5) 2.26 (−5.0) 2.39 (0.4) 2.69 (13.0) 0.265a
 Mon % 3.56 3.72 (4.5) 4.68 (31.4) 5.08 (42.6) 4.57 (28.4) 5.29 (48.6) 0.095b
 Bas % 0.30 0.36 (20.0) 0.33 (10.0) 0.34 (13.3) 0.31 (3.3) 0.32 (6.6) 0.804a
Open in a new tab

Abbreviations: TWBC = total white blood cells, Neut = Neutrophils, Lymp = Lymphocytes, Eos = Eosinophils, Mon = Monocytes, Bas = Basophils, % = Percent, L = Liter, ANOVA = Analysis of variance, SD = Standard deviation

*p values less than 0.001, ap-value determined by Kruskal-Wallis H test, bp-value determined by one-way ANOVA

Storage related changes in RBC and RBC indices

This study also found significant changes in RBC count and RBC indices in all the three donor groups (Table 2). In all donor groups, there were consecutive reductions of RBC count, haemoglobin level, and HCT in all successive weekly estimations compared to baseline values. Whereas the most significant reduction in RBC count occurred in the SCT blood donor group, (26.5% decrease compared to baseline), the highest reductions in haemoglobin and HCT occurred in the sickle cell/malaria negative blood donor group [26.5% (Hb), and 25.2% (HCT) reductions compared to baseline]. Also, RDW-CV% values consecutively increased in all donor groups with respect to successive weekly measurement. However, whereas weekly MCV and MCH values consistently decreased in asymptomatic malaria donor group, these values fluctuated in SCT or sickle cell/malaria negative donor groups.

Table 2.

RBC and RBC indices storage changes in donor blood

RBC and RBC indices Baseline Mean Week 1 Mean (%∆) Week 2 Mean (%∆) Week 3 Mean (%∆) Week 4 Mean (%∆) Week 5 Mean (%∆) P-values
Sickle cell and malaria negative donor blood
 RBC (×1012/L) 4.72 4.27 (−9.5) 4.08 (− 13.5) 4.03 (− 14.6) 3.98(−15.6) 4.04 (− 14.4) 0.147a
 Hb (g/dl) 13.17 11.35 (−13.8) 10.49 (− 20.3) 9.97 (− 24.3) 10.06 (−23.6) 9.74 (−26.0) 0.022a
 HCT (%) 37.54 33.52 (−10.7) 28.83 (− 23.2) 28.52 (−24.0) 28.48(− 24.1) 28.06(− 25.2) 0.013a
 MCV (fL) 75.88 76.99 (1.5) 75.34 (−0.7) 74.37 (−1.9) 74.67 (−1.6) 75.22 (− 0.9) 0.952a
 MCH (pg) 26.70 26.23 (−1.7) 27.61 (3.4) 25.85 (−3.1) 26.39 (−1.1) 26.14 (−2.0) 0.924a
 MCHC (g/dl) 32.47 31.39 (−3.3) 33.58 (3.4) 31.90 (−1.7) 32.45 (−0.6) 31.92 (−1.6) 0.932a
 RDW_CV (%) 14.14 14.14 (0.0) 14.20 (0.4) 15.02 (6.2) 14.63 (3.4) 14.76 (4.3) 0.486b
 RDW_SD (fL) 32.38 32.38 (0.0) 33.55 (3.6) 31.76 (−1.9) 32.14 (−0.7) 30.17 (−6.8) 0.756b
Sickle cell trait donor blood
 RBC (×1012/L) 4.75 4.06 (−14.5) 3.58 (−24.6) 3.57 (−24.8) 3.56 (−25.0) 3.49 (−26.5) 0.016a
 Hb (g/dl) 14.45 12.84 (−11.1) 12.47 (−13.7) 11.47 (−20.6) 11.57 (− 19.9) 11.43 (−20.8) 0.002a
 HCT (%) 39.96 36.75 (−8.0) 33.34 (−16.5) 33.29 (−16.7) 32.55 (− 18.5) 33.22 (− 16.8) 0.005a
 MCV (fL) 82.54 86.71 (5.0) 82.02 (−0.6) 81.27 (−1.5) 82.03 (− 0.61) 82.95 (0.4) 0.573a
 MCH (pg) 30.36 30.29 (−0.2) 30.39 (0.3) 28.54 (−5.9) 29.12 (−4.0) 28.43 (−6.3) 0.424a
 MCHC (g/dl) 36.75 34.99 (−4.7) 37.08 (0.9) 34.96 (− 4.8) 35.50 (−3.4) 34.30 (−6.6) 0.001a
 RDW_CV (%) 14.75 14.75 (0.0) 14.91 (1.0) 15.30 (3.7) 15.03 (1.8) 23.68 (60.5) 0.518b
 RDW_SD (fL) 35.59 35.59 (0.0) 36.54 (2.6) 33.80 (5.0) 34.06 (4.2) 31.83 (10.5) 0.082b
Asymptomatic malaria donor blood
 RBC (×1012/L) 5.00 4.48 (−10.4) 4.02 (−19.6) 4.00 (−20.0) 3.96 (−20.8) 3.72 (−25.6) 0.001*,a
 Hb (g/dl) 14.73 13.06 (−11.3) 12.12 (−17.7) 11.82 (− 19.7) 11.98 (− 18.6) 11.53 (−21.7) 0.001*,a
 HCT (%) 42.72 38.83 (−9.1) 34.04 (−20.3) 34.32 (− 19.6) 34.33 (−19.6) 33.38 (−21.8) 0.001*,a
 MCV (fL) 89.15 87.66 (−1.6) 82.04 (−7.9) 81.81 (−8.2) 82.68 (−7.2) 83.31 (−6.5) 0.067a
 MCH (pg) 30.85 29.42 (−4.6) 29.66 (−3.8) 28.13 (−8.8) 29.20 (−5.3) 29.15 (−5.5) 0.320a
 MCHC (g/dl) 35.48 33.57 (−5.3) 36.22 (2.0) 34.45 (2.9) 35.38 (−0.2) 35.01 (−1.3) 0.002b
 RDW_CV (%) 14.81 14.81 (0.0) 15.80 (6.6) 16.39 (10.6) 16.16 (9.1) 16.26 (9.7) 0.024a
 RDW_SD (fL) 36.53 36.53 (0.0) 35.75 (−2.1) 33.82 (−7.4) 34.49 (−5.5) 34.49 (−5.5) 0.267a
Open in a new tab

Abbreviations: RBC = Red blood cells, Hb = Haemoglobin, HCT = Haematocrit, MCV = Mean cell volume, MCH = Mean cell haemoglobin, MCHC = Mean cell haemoglobin concentration, RDW_CV = Red cell distribution width coefficient of variation, RDW_SD = Red cell distribution width standard deviation, L = Litre, fL = Fentolitre, pg = picogram

*p values less than 0.001; ap-value determined by one-way ANOVA; bp-value determined by Kruskal-Wallis H test

Storage related changes in platelets and platelet indices

Changes in platelet count and related platelet indices were also observed in the donor population (Table 3). Consecutively, weekly platelet count estimates successively decreased in all blood donor groups; the highest significant reduction occurring in asymptomatic malaria blood donor group (49.9% decrease compared to baseline). Also, whereas weekly MPV and P_LCR successively increased in sickle cell/malaria negative and asymptomatic malaria donor group, the levels of these measurements fluctuated in the SCT blood donor group.

Table 3.

Platelet and platelet indices storages changes in donor blood

Baseline Mean Week 1 Mean (%∆) Week 2 Mean (%∆) Week 3 Mean (%∆) Week 4 Mean (%∆) Week 5 Mean (%∆) F P-value
Sickle cell and malaria negative donor blood
 Plt (×109/L) 224.10 199.55(10.9) 171.10(23.6) 162.60(27.4) 167.40(25.3) 139.30(37.8) 4.09 0.003
 MPV (fL) 8.45 9.05(7.1) 9.93(17.5) 9.71(14.9) 9.17(8.5) 10.10(19.5) 8.18 0.001*
 PDW (fL) 12.74 12.41(2.5) 13.93(9.3) 13.00(2.0) 11.98(5.9) 13.63(6.9) 1.00 0.425
 PCT (%) 0.18 0.16(11.1) 0.17(5.5) 0.15(16.6) 0.15(16.6) 0.13(27.7) 1.09 0.374
 P_LCR (%) 18.15 20.11(10.7) 21.86(20.4) 22.15(22.0) 19.21(5.8) 24.18(33.2) 1.24 0.304
Sickle cell trait donor blood
 Plt (×109/L) 225.90 214.10(5.2) 185.20(18.0) 189.40(16.1) 207.80(8.0) 167.61(25.8) 1.25 0.301
 MPV (fL) 8.69 8.53(1.8) 9.83(13.1) 9.78(12.5) 9.83(13.1) 10.45(20.2) 3.85 0.005
 PDW (fL) 12.31 12.03(2.2) 13.89(12.8) 13.75(11.6) 13.72(11.4) 15.54(26.2) 1.55 0.189
 PCT (%) 0.19 0.19(0.0) 0.18(5.2) 0.18(5.2) 0.20(5.2) 0.18(5.2) 0.31 0.903
 P_LCR (%) 16.62 16.19(2.5) 20.02(20.4) 21.65(30.2) 20.35(22.4) 24.28(46.0) 2.09 0.080
Asymptomatic malaria donor blood
 Plt (×109/L) 191.90 141.30(26.3) 132.70(30.8) 118.40(38.3) 106.80(44.3) 96.10(49.9) 7.47 0.001*
 MPV (fL) 8.59 8.59(0.0) 9.87(14.9) 9.93(15.6) 9.10(5.9) 10.19(18.6) 2.52 0.040
 PDW (fL) 13.90 13.90(0.0) 14.28(2.7) 14.75(6.1) 12.25(11.8) 15.98(14.9) 1.49 0.208
 PCT (%) 0.15 0.15(0.0) 0.16(6.6) 0.15(0.0) 0.16(6.6) 0.14(6.6) 0.41 0.835
 P_LCR (%) 19.48 19.48((0.0) 22.19(13.9) 22.17(13.8) 21.40(9.8) 26.89(38.0) 1.33 0.265
Open in a new tab

Abbreviations: Plt = Platelets, PMV = Mean platelet volume, PDW=Platelet distribution width, PCT = Plateletcrit, P_LCR = Platelet large cell ratio

*p values less than 0.001

Storage related changes in leukocyte ratios

There was progressive increase in lymphocyte-to-eosinophils ratio (LER) in the three blood donor groups but the differences in the SCT/malaria negative group were not significant (%∆ 4.0–20.7%, F = 2.363, p = 0.052) whilst significant differences were seen in the SCT (%∆ 55.9–178%, F = 5.16, p = < 0.05) and the malaria positive donor group (%∆ 35.5–514.7%, F = 4.46, p = < 0.05). In addition to LER, significant increase in lymphocyte-to-basophils ratio (LBR) was observed in malaria positive donor group (%∆ 25.3–151.9%, F = 5.11, p = < 0.05) but not in SCT group (F = 0.73, p = 0.602) and SCT/malaria negative group (F = 0.34, p = 0.882). There were gradual increases in lymphocytes-to-monocytes ratio (LMR) in both the SCT and the malaria positive group but the differences between the values were not significant. Lymphocyte-to-neutrophil ratio (LNR) increased in the three groups but significant increases were seen in SCT (29.1–308.8%, F = 4.53, p = 0.001) and malaria positive blood (75–437.5%, F = 10.9, p < 0.05) (Table 4).

Table 4.

Storage related changes in leucocyte ratios

Leukocyte ratio Baseline Mean Week 1 Mean(%∆) Week 2 Mean(%∆) Week 3 Mean(%∆) Week 4 Mean(%∆) Week 5 Mean(%∆) F P-value
Sickle cell and malaria negative donor blood
 LER 19.8 20.6(4.0) 20.3(2.5) 21.2(7.1) 22.5(13.6) 23.9(20.7) 2.36 0.052
 LMR 9.7 10.0(3.1) 9.0(7.2) 8.7(10.3) 10.2(5.2) 10.0(3.1) 0.42 0.828
 LBR 184 205(11.4) 128(30.4) 130(29.3) 150(18.5) 149(19.0) 0.34 0.882
 LNR 0.73 0.83(13.7) 1.12(53.4) 1.17(60.3) 1.33(82.2) 1.88(157.5) 1.44 0.222
Sickle cell trait donor blood
 LER 11.8 18.4(55.9) 26.8(127.1) 36.1(205.9) 38.5(226.3) 32.8(178.0) 5.16 0.001*
 LMR 12.3 13.1(6.5) 14.2(15.4) 16.9(37.4) 22.4(82.1) 13.9(13.0) 1.95 0.100
 LBR 198 177(10.6) 141(28.8) 169(14.6) 183(7.6) 169(14.6) 0.73 0.602
 LNR 0.79 1.02(29.1) 1.42(79.8) 2.22(181.0) 2.83(258.2) 3.23(308.8) 4.53 0.001
Asymptomatic malaria donor blood
 LER 6.8 9.2(35.3) 19.3(183.8) 19.0(179.4) 23.0(238.2) 41.8(514.7) 4.46 0.001
 LMR 5.9 8.7(47.5) 10.6(79.7) 11.3(91.5) 10.6(79.7) 10.8(83.1) 2.07 0.083
 LBR 79 99(25.3) 127(60.8) 175(121.5) 181(129.1) 199(151.9) 5.11 0.001*
 LNR 0.32 0.56(75.0) 1.07(234.4) 1.42(343.7) 1.27(296.9) 1.72(437.5) 10.9 0.001*
Open in a new tab

Abbreviations: LER-lymphocytes-to-eosinophils ratio, LMR-lymphocytes-to-monocytes ratio, LBR-lymphocytes-to-basophils ratio, LPR-lymphocyte-to-platelets ratio, LNR-lymphocytes-to-neutrophils ratio

*p-value less than 0.001

Moreover, when the weekly estimates in haematological parameters were compared to baseline using paired t-test analyses, most of the significant changes occurred in the SCT blood donors or the asymptomatic malaria positive blood donors (Additional file 1: Table S1).

Effect of storage on haemolytic and biochemical parameters in donor blood

The storage lesions related to haemolytic and biochemical parameters presented in Table 5. The plasma haemoglobin and %haemolysis consecutively increased with the successive weekly estimations in all blood donor groups. Additionally, weekly LDH and plasma potassium levels consecutively increased in weekly estimates compared to baseline in all blood donor groups. Whereas the most significant increase in LDH occurred in asymptomatic malaria blood donor group (319% increase over baseline), the most significant increase in plasma potassium levels occurred in SCT blood donor group (382% increase over baseline levels). However, weekly plasma sodium and chloride levels successively decreased in all blood donor group; the highest significant reductions occurring in asymptomatic malaria blood donor group [10.0% (sodium) and 21.3% (chloride) decreases compared to baseline].

Table 5.

Analysis of haemolytic and biochemical parameters in donor blood stored for baseline, week 1, week 3 and week 5

Haemolytic parameters Baseline Mean Week 1 Mean (%∆) Week 3 Mean (%∆) Week 5 Mean (%∆) P-value
Sickle cell and malaria negative donor blood
 Plasma Hb (g/dl) 0.00 0.10 0.11(9.1)c 0.21(52.4)c 0.001*,a
 % Haemolysis 0.00 0.52 0.75(30.7)c 1.44(63.9)c 0.001*,a
 LDH (U/L) 199.40 319.20 (60.1) 428.00 (114.6) 522.70 (162.1) 0.001*,a
 Potassium (mmol/L) 4.14 5.65 (56.5) 7.72 (86.5) 10.03(142.3) 0.001*,b
 Sodium (mmol/L) 137.94 134.52 (−2.5) 130.00 (−5.7) 126.33 (−8.4) 0.001*,a
 Chloride (mmol/L) 98.66 89.06 (−3.5) 84.98 (−13.9) 83.55 (−15.3) 0.001*,b
Sickle cell trait donor blood
 Plasma Hb (g/dl) 0.00 0.24 0.37(35.1)c 0.46(47.8)c 0.001*,b
 % Haemolysis 0.00 1.16 2.08(44.2)c 2.62(55.7)c 0.001*,a
 LDH (U/L) 207.10 329.20 (59.0) 491.60 (137.4) 610.40 (194.7) 0.001*,a
 Potassium (mmol/L) 4.27 6.95 (62.8) 12.14 (184.3) 20.58 (382.0) 0.001*,a
 Sodium (mmol/L) 139.51 136.74 (−2.0) 133.67 (−4.2) 130.35 (−6.5) 0.001*,a
 Chloride (mmol/L) 99.63 90.77 (−8.9) 83.99 (− 15.7) 78.50 (−21.2) 0.001*,b
Asymptomatic malaria donor blood
 Plasma Hb (g/dl) 0.00 0.22 0.26(15.4)c 0.32(31.3)c 0.001*,a
 % Haemolysis 0.00 1.00 1.46(31.5)c 1.90(47.3)c 0.001*,a
 LDH (U/L) 192.30 418.70 (117.7) 596.60 (210.4) 806.70 (319.5) 0.001*,b
 Potassium (mmol/L) 4.38 8.38 (91.3) 11.66 (166.2) 15.01 (242.7) 0.001*,b
 Sodium (mmol/L) 140.72 135.17 (−3.9) 130.16 (−7.5) 125.60 (−10.0) 0.001*,a
 Chloride (mmol/L) 100.62 91.00 (−9.6) 85.71 (−14.8) 79.21 (−21.3) 0.001*,a
Open in a new tab

Abbreviations: LDH = Lactate dehydrogenase, SD = Standard deviation, Hb = Haemoglobin

*p values less than 0.001, ap-value determined by Kruskal-Wallis H test, bp-value determined by one-way ANOVA, c %Δ calculated with respect to week 1 mean values

Comparison of haemolytic and biochemical parameters across blood donor groups

The storage lesions in donor blood were quantitatively compared across the groups with respect to the weeks in storage (Table 6). Plasma haemoglobin and %haemolysis were significantly higher in SCT blood donors with respective weekly measurements compared to the other blood donor groups. However, respective weekly plasma LDH levels were significantly higher in asymptomatic malaria blood donor group compared to respective values in the other blood donor groups. Additionally, although baseline plasma potassium levels were comparable in all blood donor groups, weekly plasma potassium levels were respectively higher in asymptomatic malaria or SCT blood donor group compared to sickle cell and malaria negative blood donor group. Moreover, plasma sodium and chloride significantly decreased in the asymptomatic malaria group compared to the other groups.

Table 6.

ANOVA analysis of inter-donor category biochemical and haemolytic parameters

Parameters Sickle cell/malaria negative donors Mean ± SD Sickle cell trait donors Mean ± SD Asymptomatic malaria donors Mean ± SD F P-value
Baseline
 Plasma Hb 0.00 0.00 0.00
 % haemolysis 0.00 0.00 0.00
 LDH (U/L) 202.45 ± 20.51 202.90 ± 18.91 173.20 ± 63.74 1.76 0.188
 Potassium (mmol/L) 4.15 ± 0.70 4.22 ± 0.71 4.01 ± 1.50 0.39 0.681
 Sodium (mmol/L) 138.44 ± 2.40 139.52 ± 2.54 126.37 ± 44.53 3.16 0.057
 Chloride (mmol/L) 98.78 ± 1.66 99.88 ± 1.78 90.37 ± 31.87 2.68 0.085
Week 1
 Plasma Hb 0.10 ± 0.00 0.25 ± 0.13 0.20 ± 0.09 23.6 0.001*
 % haemolysis 0.51 ± 0.05 1.12 ± 0.27 1.01 ± 0.35 20.7 0.001*
 LDH (U/L) 318.36 ± 29.30 346.00 ± 78.68 370.90 ± 137.89 14.6 0.001*
 Potassium (mmol/L) 5.54 ± 0.41 7.02 ± 1.15 8.46 ± 0.75 33.6 0.001*
 Sodium (mmol/L) 134.90 ± 3.06 136.95 ± 2.88 121.09 ± 42.80 1.16 0.326
 Chloride (mmol/L) 89.60 ± 3.12 90.53 ± 4.19 81.74 ± 28.74 1.47 0.246
Week 3
 Plasma Hb 0.11 ± 0.03 0.39 ± 0.12 0.23 ± 0.11 22.2 0.001*
 % haemolysis 0.76 ± 0.35 2.21 ± 0.62 1.37 ± 0.41 17.3 0.001*
 LDH (U/L) 436.36 ± 46.31 491.10 ± 47.17 605.77 ± 61.98 33.0 0.001*
 Potassium (mmol/L) 8.05 ± 1.39 12.02 ± 1.61 11.83 ± 1.47 40.3 0.001*
 Sodium (mmol/L) 130.88 ± 4.23 133.45 ± 3.42 129.00 ± 3.51 3.74 0.035
 Chloride (mmol/L) 85.61 ± 3.91 83.37 ± 3.44 85.37 ± 2.85 0.73 0.487
Week 5
 Plasma Hb 0.20 ± 0.04 0.48 ± 0.19 0.28 ± 0.14 8.84 0.001*
 % haemolysis 1.46 ± 0.51 2.75 ± 1.00 1.78 ± 0.65 4.48 0.001*
 LDH (U/L) 536.09 ± 58.71 631.90 ± 109.29 798.00 ± 64.38 13.0 0.001*
 Potassium (mmol/L) 11.35 ± 4.46 19.48 ± 2.86 15.18 ± 1.98 8.25 0.001*
 Sodium (mmol/L) 127.64 ± 6.00 129.62 ± 5.17 124.73 ± 4.79 9.70 0.001*
 Chloride (mmol/L) 84.27 ± 4.29 77.81 ± 4.31 78.61 ± 3.44 1.22 0.309
Open in a new tab

Abbreviations: LDH = Lactate dehydrogenase, SD = Standard deviation, Hb = Haemoglobin

*p-values less than 0.001

Discussion

Preservation and long term storage of red blood cells is essential for continuous supply of safe blood for clinical use [24]. Previous studies have found deleterious storage effect on blood cell morphology and functions [31–33]. This study found similar trend of storage lesion in whole blood stored up to 5 weeks but the changes were more pronounced in blood collected from sickle cell trait (SCT) donors or donors infected asymptomatically with malaria parasites. In the three groups, gradual reduction in total white cells and neutrophils and progressive increase in lymphocytes were observed; a phenomenon that was previously observed by Adias [24]. This observation probably can be due to cell loss and cytotoxic effect of histamine and cytokines released by neutrophils [34]. TWBC, neutrophils and eosinophils cells lost were more evident in the SCT or asymptomatic malaria positive stored blood than sickle cell and malaria negative blood. It was observed that lymphocytes to eosinophils, monocytes, basophils and neutrophils ratios were elevated in the three groups but in all cases significant elevations occurred in SCT and malaria positive donor blood. Insignificant elevations were observed in SCT/malaria negative blood. Elevation in LER, LMR, LBR and LNR values occurred as a result of progressive elevations in mean lymphocytes percentages and reduction in mean absolute eosinophils, monocytes, basophils and neutrophils. This predisposes blood recipients to bacterial invasion and increased proliferation of pathogenic bacterial [35, 36]. Fever is a common symptom of sepsis [37]. Donor blood with high LER, LMR, LBR and LNR could cause pathogen induced acute or delayed febrile reactions in recipients with low leukocyte count.

In sickle cell and malaria negative group, red blood cells were relatively stable during storage but in the SCT or asymptomatic malaria donor group, there were significant reduction in red blood cells, haemoglobin and haematocrit. These haematological changes corresponded with gradual increases in plasma haemoglobin due to increased red cell breakdown as well as gradual elevation of potassium ions and lactate dehydrogenase during storage. These observations could be as a result of haemoglobin S erythrocytes fragility subsequent to polymerization of haemoglobin S and reduced deformability and loss of red cell elasticity during storage due to low oxygen tension and low pH storage medium [38–40] on the one hand, as well as metabolically active intra-erythrocytic Plasmodium parasites could account for these haematological changes. Malaria parasites have been found to be viable in stored blood for at least the first 14 days [41]. When one malaria parasite per microliter of blood is found, that converts to about 500,000 red cells parasitized in a unit of blood [42]. These viable parasites are enough to cause significant haematological derangement in the blood of an infected healthy donor during storage. One of the goals of haemo-transfusion is to restore tissue oxygenation [43]. Stored blood from SCT and asymptomatic malaria donors may develop storage lesions over time due to polymerization of haemoglobin S in SCT donor blood, loss of deformability and increased osmotic fragility which could compromise their haemorheological properties and oxygen binding and delivery capacity [44, 45].

Storage of blood collected from SCT and asymptomatic malaria donors were significantly associated with red cell lysis and elevated plasma haemoglobin. On day of blood collection, donor plasma was free of haemoglobin as well as insignificant differences in potassium, sodium, LDH and chloride in all the donor groups. However at week 1, plasma haemoglobin was 2.4 times higher in SCT donor blood and 2.2 higher in asymptomatic malaria blood compared to sickle cell and malaria negative group. At week 3, plasma haemoglobin was 3.36 times and 2.36 times higher in SCT and asymptomatic malaria donor blood respectively, and at week 5, plasma haemoglobin was 2.2 times higher in SCT and 1.5 higher in asymptomatic malaria group. Excess plasma haemoglobin increased over time in the SCT and the asymptomatic malaria donor groups. At week 1, the percentage haemolysis in the SCT and asymptomatic malaria was more than the permissible level of 0.8%. Blood with % haemolysis of 0.8% is not recommended for clinical use [30]. Excess haemoglobin has been found to have negative influence on the intravascular nitric oxide (NO) metabolism after transfusion. Plasma haemoglobin has been found to be a potent scavenger of NO, the most important endogenous vasodilator. In view of this, transfusing blood with high concentration of plasma haemoglobin could decrease NO bioavailability, decreased organ perfusion, increased organ injury [46, 47] and increased mortality in patients with sepsis [48]. Patients with organ failure and patients with septic shock may worsen their condition when transfused with blood with high plasma haemoglobin content. Potassium increased in the SCT and asymptomatic malaria groups and continued till their respective levels were 4.8 and 3.4 times higher than the baseline at week 5, a factor far more than was observed in the sickle cell/malaria negative group. It is recommended to include malaria and sickle cells screening into donor screening protocols to prevent potassium and free haemoglobin overload. In addition, the clinical impact of transmitting malaria to the recipient, albeit asymptomatic in the donor, merits consideration with recommendations to prevent such transmissions [49].

Conclusion

Storage of SCT and malaria infected blood affected all the cell lines. At week 1, total white blood cells, neutrophils, red cells, haemoglobin and haematocrit began to fall significantly in SCT and asymptomatic donor blood. Significant elevation plasma haemoglobin, increase in % haemolysis above the permissible level of 0.8% and potassium elevation above the upper reference range for Ghanaian adults (5.2 mmol/L) [50] were observed. Significant reduction in red blood cells coupled with significant elevations in plasma haemoglobin, intracellular potassium and lactate dehydrogenase can led to the conclusion that significant number of red cells haemolysis in the experimental set up. This assumption was confirmed by steady elevation of % haemolysis over the storage weeks.

Limitations of the study

Malaria parasites were not quantified in the infected blood units. The analysis did not take into consideration the blood group and Rhesus phenotypes of the study units. The gender of the blood donors was unknown. Haemoglobin S was not quantified in the sickle cell trait donor blood.

Additional file

Additional file 1: (20.3KB, docx)

Table S1. Paired sample analysis in haematological parameters among the groups: baseline vs. week 1–3. (DOCX 20 kb)

Acknowledgements

The authors are thankful to the management and staff of National blood service, Ghana for collaborating with us in implementing the study. We are also grateful to Linda Baafi (Ga West Municipal Hospital Laboratory) for her voluntary participation in performing the biochemical analysis. Finally we are grateful to the National Malaria Control Programme Ghana for supplying us with malaria rapid diagnostic test kits.

Funding

The research was 100% funded by the corresponding author.

Availability of data and materials

The datasets generated and/or analyzed during the current study are available in Harvard Dataverse repository, doi:10.7910/DVN/RFBNFN

Abbreviations

2,3 BPG

2,3-biphosphoglycerate

ANOVA

One-way analysis of variance

ATP

Adenosine triphosphate

Bas

Basophils

CPDA

Citrate Phosphate Dextrose Adenine

Eos

Eosinophils

fL

Fentoliter

GHS

Ghana Health Service

Hb

Haemoglobin

HCT

Haematocrit

LBR

Lymphocytes-to-basophils ratio

LER

Lymphocytes-to-eosinophils ratio

LMR

Lymphocytes-to-monocytes ratio

LNR

Lymphocytes-to-neutrophils ratio

Lymp

Lymphocytes

MCH

Mean cell haemoglobin

MCHC

Mean cell haemoglobin concentration

MCV

Mean cell volume

Mon

Monocytes

NBSG

National Blood Service Ghana

Neut

Neutrophils

P_LCR

Platelet large cell ratio

PCT

Plateletcrit

PDW

Platelet distribution width

pg

pictogram

Plt

Platelets

PMV

Mean platelet volume

RBC

Red blood cells

RDW_CV

Red cell distribution width coefficient of variation

RDW_SD

Red cell distribution width standard deviation

SCT

Sickle cell trait

SD

Standard deviation

SSA

sub-Saharan Africa

TTIs

Transfusion transmitted infections

TWBC

Total white blood cell

Authors’ contributions

AE, AP, EYA, AOD conceived, designed the study, collected the data, performed and validated the laboratory findings and drafted the manuscript. TDE performed the statistical analysis. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Ethical approval of this study was granted by National Blood Service Ghana (NBSGRD/18903/01) and Ghana Health Service Ethical Review Committee (GHS-REC002/03/18) approved the study. Consent to participate was not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Enoch Aninagyei, Email: enochaninagyei@yahoo.com.

Desmond Omane Acheampong, Email: dacheampong@ucc.edu.gh.

References

  • 1.Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, Newman RD. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007;7(2):93–104. doi: 10.1016/S1473-3099(07)70021-X. [DOI] [PubMed] [Google Scholar]
  • 2.Belizario VY, Saul A, Bustos MD, Lansang MA, Pasay CJ, Gatton M, Salazar NP. Field epidemiological studies on malaria in a low endemic area in the Philippines. Acta Trop. 1997;63:241–256. doi: 10.1016/S0001-706X(96)00624-9. [DOI] [PubMed] [Google Scholar]
  • 3.Roucher C, Rogier C, Dieye-Ba F, Sokhna C, Tall A, Trape J-F. Changing malaria epidemiology and diagnostic criteria for Plasmodium falciparum clinical malaria. PLoS One. 2012;7:e46188. doi: 10.1371/journal.pone.0046188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.da Silva-Nunes M, Ferreira MU. Clinical spectrum of uncomplicated malaria in semi-immune Amazonians: beyond the ‘symptomatic’ vs ‘asymptomatic’ dichotomy. Memorias Do Instituto Oswaldo Cruz. 2007;102(3):341–347. doi: 10.1590/S0074-02762007005000051. [DOI] [PubMed] [Google Scholar]
  • 5.Harris I, Sharrock WW, Bain LM, et al. A large proportion of asymptomatic Plasmodium infections with low and sub-microscopic parasite densities in the low transmission setting of Temotu Province, Solomon Islands: challenges for malaria diagnostics in an elimination setting. Malar J. 2010;9:254. doi: 10.1186/1475-2875-9-254. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Hoyer S, Nguon S, Kim S, Habib N, Khim N, Sum S, et al. Focused screening and treatment (FSAT): a PCR-based strategy to detect malaria parasite carriers and contain drug resistant P. falciparum, Pailin, Cambodia. PLoS One. 2012;7(10):e45797. doi: 10.1371/journal.pone.0045797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Owusu-Ofori A, Gadzo G, Bates I. Transfusion-transmitted malaria: donor prevalence of parasitaemia and a survey of healthcare workers knowledge and practices in a district hospital in Ghana. Malar J. 2016;15:234–241. doi: 10.1186/s12936-016-1289-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Mogtomo ML, Fomekong SL, Kuate HF, Ngane AN. Screening of infectious microorganisms in blood banks in Douala (1995-2004) Sante. 2009;19:3–8. doi: 10.1684/san.2009.0144. [DOI] [PubMed] [Google Scholar]
  • 9.Diop S, Ndiaye M, Seck M, Knight B, Jambou R, Sarr A, Dieye TN, Toure AO, Thiam D, Diakhate L. Prevention of transfusion transmitted malaria in endemic area. Clinical and biological transfusion. 2009;16:454–459. doi: 10.1016/j.tracli.2009.02.004. [DOI] [PubMed] [Google Scholar]
  • 10.Kinde-Gazard OJ, Gnahoui I, Massougbodji A. The risk of malaria transmission by blood transfusion at Cotonou, Benin. Cahiers Sante. 2000;10(6):389–392. [PubMed] [Google Scholar]
  • 11.Oladeinde BH, Omoregie R, Osakue EO, Onaiwu TO Asymptomatic malaria among blood donors in Benin City Nigeria. Iranian J Parasitol. 2014;9(3):415–422. [PMC free article] [PubMed] [Google Scholar]
  • 12.Aguiar KM, Maia CN. Prevalence of hemoglobin S in blood donors at the Hemocentro regional in the town of Montes Claros. Minas Gerais RBAC. 2011;43(4):284–287. [Google Scholar]
  • 13.Antwi-Baffour S, Asare RO, Adjei JK, Kyeremeh R, Adjei DN. Prevalence of hemoglobin S trait among blood donors: a cross-sectional study. BMC Res Notes. 2015;8:583. doi: 10.1186/s13104-015-1583-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Omotade OO, Kayode CM, Falade SL, Ikpeme S, Adeyemo AA, Akinkugbe FM. Routine screening for sickle cell haemoglobinopathy by electrophoresis in an infant welfare clinic. West Afr J Med. 1998;17:91–94. [PubMed] [Google Scholar]
  • 15.Tubman VN, Marshall R, Jallah W. Newborn screening for sickle cell disease in Liberia: a pilot study. Pediatr Blood Cancer. 2016;63:671–676. doi: 10.1002/pbc.25875. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Ndeezi G, Kiyaga C, Hernandez AG, Munube D, Howard TA, Ssewanyana I, Nsungwa J, Kiguli S, Ndugwa CM, Ware RE, Aceng JR. Burden of sickle cell trait and disease in the Uganda sickle surveillance study (US3): a cross-sectional study. Lancet Global Health. 2016;4:e195–e200. doi: 10.1016/S2214-109X(15)00288-0. [DOI] [PubMed] [Google Scholar]
  • 17.Ama V, Kengne AP, Nansseu NJ, Nouthe B, Sobngwi E. Would sickle cell trait influences the metabolic control in sub-Saharan individuals with T2D? Diabet Med. 2012;29:334–337. doi: 10.1111/j.1464-5491.2012.03620.x. [DOI] [PubMed] [Google Scholar]
  • 18.Elguero E, Delicat-Loembet LM, Rougeron V, Arnathau C, Roche B, Becquart P, Gonzalez JP, Nkoghe D, Sica L, Leroy EM, Durand P, Ayala FJ, Ollomo B, Renaud F, Prugnolle F. Malaria continues to select for sickle cell trait in Central Africa. Proc Natl Acad Sci U S A. 2015;112:7051–7054. doi: 10.1073/pnas.1505665112. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Grignani C, Iamamoto C, Goncalves T, Mashima D, et al. Prevalence of hemoglobin AS among blood donors from Londrina - Parana. RBAC. 2006;38(4):259–262. [Google Scholar]
  • 20.Goncalves LB, Duarte EHG, Cabral MD. Prevalence of hemoglobin S in blood donors in the hospital Dr. Agostinho Neto, Praia City – Cape Verde. Sci J Public Health. 2015;3(5):600–604. doi: 10.11648/j.sjph.20150305.11. [DOI] [Google Scholar]
  • 21.Garba N, Danladi SB, Abubakar HB, Ahmad SG, Gwarzo MY. Distribution of Haemoglobin variants, ABO and Rh blood groups in blood donors attending Aminu Kano teaching hospital. Clin Med J. 2016;2(2):20–24. [Google Scholar]
  • 22.Adu Patrick, Simpong David Larbi, Takyi Godfred, Ephraim Richard K. D. Glucose-6-Phosphate Dehydrogenase Deficiency and Sickle Cell Trait among Prospective Blood Donors: A Cross-Sectional Study in Berekum, Ghana. Advances in Hematology. 2016;2016:1–7. doi: 10.1155/2016/7302912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Ghartimagar D. Rational clinical use of blood and blood products – a summary. J Pathol Nepal. 2017;7:1111–1117. doi: 10.3126/jpn.v7i1.16949. [DOI] [Google Scholar]
  • 24.Adias TC, Moore-Igwe B, Jeremiah ZA. Storage related Haematological and biochemical changes of CPDA-1 whole blood in a resource limited setting. J Blood Disorders Transf. 2012;3:124. doi: 10.4172/2155-9864.1000124. [DOI] [Google Scholar]
  • 25.Cheesbrough M. Blood transfusion practice: blood donation and storage of blood, district laboratory practice in tropical countries. Low price edition. Cambridge Universal Press. 2002;2:352–353. [Google Scholar]
  • 26.Koch CG, Figueroa PI, Li L, et al. Red blood cell storage: how long is too long? Ann Thorac Surg. 2013;96(5):1894–1899. doi: 10.1016/j.athoracsur.2013.05.116. [DOI] [PubMed] [Google Scholar]
  • 27.Bonaventura J. Clinical implications of the loss of vasoactive nitric oxide during red blood cell storage. Proc Natl Acad Sci U S A. 2007;104:19165–19166. doi: 10.1073/pnas.0708871105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Spinella PC, Sparrow RL, Hess JR, et al. Properties of stored red blood cells: understanding immune and vascular reactivity. Transfusion. 2011;51(4):894–900. doi: 10.1111/j.1537-2995.2011.03103.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.WHO. Guidelines on assessing donor suitability for blood donation. World Health Organization 2012. http://www.who.int/iris/handle/10665/76724. Assessed 7 Aug 2018. [PubMed]
  • 30.Sawant RB, Jathar SK, Rajadhyaksha SB, Kadam PT. Red cell hemolysis during processing and storage. Asian J Transfus Sci. 2007;1(2):47–51. doi: 10.4103/0973-6247.33446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008;358:1229–1239. doi: 10.1056/NEJMoa070403. [DOI] [PubMed] [Google Scholar]
  • 32.van de Watering L. Red cell storage and prognosis. Vox Sang. 2011;100:36–45. doi: 10.1111/j.1423-0410.2010.01441.x. [DOI] [PubMed] [Google Scholar]
  • 33.Hess JR. Red cell changes during storage. Transfus Apher Sci. 2010;43:51–59. doi: 10.1016/j.transci.2010.05.009. [DOI] [PubMed] [Google Scholar]
  • 34.Hess JR. An update on solutions for red cell storage. Vox Sang. 2006;91:13–19. doi: 10.1111/j.1423-0410.2006.00778.x. [DOI] [PubMed] [Google Scholar]
  • 35.Antoniadou A, Giamarellou H. Fever of unknown origin in febrile leukopenia. Infect Dis Clin N Am. 2007;21(4):1055–1090. doi: 10.1016/j.idc.2007.08.008. [DOI] [PubMed] [Google Scholar]
  • 36.Friese CR. Chemotherapy-induced neutropenia: important new data to guide nursing assessment and management. Cancer Ther Support Care. 2006;4(2):21–25. [Google Scholar]
  • 37.Schortgen F. Fever in sepsis. Minerva Anestesiol. 2012;78(11):1254–1264. [PubMed] [Google Scholar]
  • 38.Brandao M. M., Saad S. T. O., Cezar C. L., Fontes A., Costa F. F., Barjas-Castro M. L. Elastic properties of stored red blood cells from sickle trait donor units. Vox Sanguinis. 2003;85(3):213–215. doi: 10.1046/j.1423-0410.2003.00344.x. [DOI] [PubMed] [Google Scholar]
  • 39.Noguchi CT, Torchia DA, Schechter AN. Polymerization of hemoglobin in sickle cell trait erythrocytes and lysate. J Biol Chem. 1981;256:4168–4171. [PubMed] [Google Scholar]
  • 40.Helzlsouer KJ, Hayden FG, Rogol AD. Severe metabolic complications in a cross country runner with sickle cell trait. JAMA. 1983;249:777–779. doi: 10.1001/jama.1983.03330300061037. [DOI] [PubMed] [Google Scholar]
  • 41.Kitchen AD, Chiodini PL. Malaria and blood transfusion. Vox Sang. 2006;90(2):77–84. doi: 10.1111/j.1423-0410.2006.00733.x. [DOI] [PubMed] [Google Scholar]
  • 42.Owusu-Ofori AK, Betson M, Parry CM, Stothard R, Bates I. Transfusion-transmitted malaria in Ghana. Clin Infect Dis. 2013;56(12):1735–1741. doi: 10.1093/cid/cit130. [DOI] [PubMed] [Google Scholar]
  • 43.Raat NJ, Ince C. Oxygenating the microcirculation: the perspective from blood transfusion and blood storage. Vox Sang. 2007;93:12–18. doi: 10.1111/j.1423-0410.2007.00909.x. [DOI] [PubMed] [Google Scholar]
  • 44.Kim-Shapiro DB, Lee J, Gladwin GT. Storage lesions: role of red blood cell breakdown. Transfusion. 2011;51:844–851. doi: 10.1111/j.1537-2995.2011.03100.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Aubron Cécile, Nichol Alistair, Cooper D Jamie, Bellomo Rinaldo. Age of red blood cells and transfusion in critically ill patients. Annals of Intensive Care. 2013;3(1):2. doi: 10.1186/2110-5820-3-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Donadee C, Raat NJ, Kanias T, Tejero J, Lee JS, Kelley EE, Zhao X, Liu C, Reynolds H, Azarov I, Frizzell S, Meyer EM, Donnenberg AD, Qu L, Triulzi D, Kim-Shapiro DB, Gladwin MT. Nitric oxide scavenging by red blood cell microparticles and cell-free hemoglobin as a mechanism for the red cell storage lesion. Circulation. 2011;26:465–476. doi: 10.1161/CIRCULATIONAHA.110.008698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Minneci PC, Deans KJ, Zhi H, Yuen PS, Star RA, Banks SM, Schechter AN, Natanson C, Gladwin MT, Solomon SB. Hemolysis-associated endothelial dysfunction mediated by accelerated NO inactivation by decompartmentalized oxyhemoglobin. J Clin Invest. 2005;115:3409–3417. doi: 10.1172/JCI25040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Adamzik Michael, Hamburger Tim, Petrat Frank, Peters Jürgen, de Groot Herbert, Hartmann Matthias. Free hemoglobin concentration in severe sepsis: methods of measurement and prediction of outcome. Critical Care. 2012;16(4):R125. doi: 10.1186/cc11425. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Infectious disease testing for blood transfusions. NIH Consensus Panel on Infectious Disease Testing for blood transfusions JAMA. 1995;274(17):1374–1379. doi: 10.1001/jama.1995.03530170054032. [DOI] [PubMed] [Google Scholar]
  • 50.Dosoo DK, Adu-Gyasi D, Kwara E, Ocran J, Osei-Kwakye, et al. Haematological and biochemical reference values for healthy adults in the middle belt of Ghana. PLoS ONE. 2012;7(4):e36308. doi: 10.1371/journal.pone.0036308. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Additional file 1: (20.3KB, docx)

Table S1. Paired sample analysis in haematological parameters among the groups: baseline vs. week 1–3. (DOCX 20 kb)

Data Availability Statement

The datasets generated and/or analyzed during the current study are available in Harvard Dataverse repository, doi:10.7910/DVN/RFBNFN

Articles from BMC Hematology are provided here courtesy of BMC

RESOURCES